EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte Studie

Reteplase versus Alteplase for Acute Ischemic Stroke

Shuya Li, Hong-Qiu Gu iD, Hao Li, Xuechun Wang, Aoming Jin, Shuming Guo, Guozhi Lu, Fengyuan Che, Weiwei Wang, Yan Wei, Yilong Wang, Zixiao Li und 5 weitere

New England Journal of Medicine · 27.06.2024 · 390 (24) · 2264-2273

DOI: 10.1056/nejmoa2400314 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 27.06.2024. Verfasst von Shuya Li und 16 weiteren Autor:innen. Beteiligte Einrichtung: From the Departments of Neurology (S.L., H.L., X.W., Yilong Wang, Z.L., X.M., X.Z., L.L., Yongjun Wang) and Clinical Trial Center (S.L., H.L., X.W., …. Hauptthemen laut MEDLINE: Fibrinolytic Agents, Ischemic Stroke, Recombinant Proteins, Tissue Plasminogen Activator. Die Arbeit wurde bisher 106-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Municipal Science and Technology Commission, Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Alteplase is the standard agent used in early reperfusion therapy, but alternative thrombolytic agents are needed. The efficacy and safety of reteplase as compared with alteplase in patients with acute ischemic stroke are unclear. METHODS: We randomly assigned patients with ischemic stroke within 4.5 hours after symptom onset in a 1:1 ratio to receive intravenous reteplase (a bolus of 18 mg followed 30 minutes later by a second bolus of 18 mg) or intravenous alteplase (0.9 mg per kilogram of body weight; maximum dose, 90 mg). The primary efficacy outcome was an excellent functional outcome, defined as a score of 0 or 1 on the modified Rankin scale (range, 0 [no neurologic deficit, no symptoms, or completely recovered] to 6 [death]) at 90 days. The primary safety outcome was symptomatic intracranial hemorrhage within 36 hours after symptom onset. RESULTS: A total of 707 patients were assigned to receive reteplase, and 705 were assigned to receive alteplase. An excellent functional outcome occurred in 79.5% of the patients in the reteplase group and in 70.4% of those in the alteplase group (risk ratio, 1.13; 95% confidence interval [CI], 1.05 to 1.21; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibrinolytic AgentsIschemic StrokeRecombinant ProteinsTissue Plasminogen ActivatorAgedFemaleHumansMaleMiddle AgedIntracranial HemorrhagesInjections, Intravenous

Substanzen

Fibrinolytic AgentsRecombinant ProteinsreteplaseTissue Plasminogen Activator

Autor:innen und Institutionen

  • From the Departments of Neurology (S.L., H.L., X.W., Yilong Wang, Z.L., X.M., X.Z., L.L., Yongjun Wang) and Clinical Trial Center (S.L., H.L., X.W., Yilong Wang, Z.L., X.M., X.Z., L.L., Yongjun Wang), and the China Nati…

ORCID-Profile: Hong-Qiu Gu, Yongjun Wang

Förderung

  • National Natural Science Foundation of China
  • Beijing Municipal Science and Technology Commission
  • Chinese Academy of Sciences
  • National Key Research and Development Program of China
  • Beijing Municipal Science & Technology Commission
  • Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
  • National Key R&D Program of China
  • China Resources Angde Biotech Pharma Co., Ltd.

Zitieren

APA

Li, S., Gu, H. Q., Li, H., Wang, X., Jin, A., Guo, S., Lu, G., Che, F., Wang, W., Wei, Y., Wang, Y., Li, Z., Meng, X., Zhao, X., Liu, L., Wang, Y., & RAISE Investigators (2024). Reteplase versus Alteplase for Acute Ischemic Stroke. New England Journal of Medicine, 390(24), 2264-2273. https://doi.org/10.1056/nejmoa2400314

Vancouver

Li S, Gu HQ, Li H, Wang X, Jin A, Guo S, et al. Reteplase versus Alteplase for Acute Ischemic Stroke. New England Journal of Medicine. 2024;390(24):2264-2273. doi:10.1056/nejmoa2400314

BibTeX
@article{Li2024,
  author = {Li, Shuya and Gu, Hong-Qiu and Li, Hao and Wang, Xuechun and Jin, Aoming and Guo, Shuming and Lu, Guozhi and Che, Fengyuan and Wang, Weiwei and Wei, Yan and Wang, Yilong and Li, Zixiao and Meng, Xia and Zhao, Xingquan and Liu, Liping and Wang, Yongjun and RAISE Investigators, RAISE Investigators},
  title = {Reteplase versus Alteplase for Acute Ischemic Stroke},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {24},
  pages = {2264--2273},
  doi = {10.1056/nejmoa2400314}
}
Kostenlos starten →